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Abstract
Background:  Systemic inflammatory response syndrome is one of the major pathobiologic
processes underlying severe acute pancreatitis and the degree of macrophage activation could be
one of the factors that finally determine the severity of the disease. We evaluated the activation
phenotype in peritoneal macrophages during the progression of an experimental model of acute
pancreatitis induced in rats by intraductal administration of 5% sodium taurocholate and the effect
of IL-4 and IL-13 to modulate this activation.
Samples of pancreas, lung and adipose tissue as well as plasma were also obtained. In some animals
IL4 and IL13 were injected 1 h after induction in order to modulate macrophage activation. The
expressions of TNFα and Mannose Receptor, as indicators of classical and alternative macrophage
activation, were evaluated. Levels of myeloperoxidase and plasma lipase were determined to
evaluate the severity of the inflammatory process. The stability of IL-4 in ascitic fluid and plasma
was evaluated.
Results:  Peritoneal macrophages showed a classical M1 activation clearly induced 3 h after
pancreatitis induction and maintained until 18 h. Treatment with IL-4 and IL-13 reversed the
activation of macrophages from a classical M1 to alternative M2 in vitro, but failed to modulate the
response of peritoneal macrophages in vivo despite a reduction in inflammation was observed in
lung and adipose tissue. Finally, IL-4 shows a short half-live in ascitic fluid when compared with
plasma.
Conclusion:  Peritoneal macrophages adopt a pro-inflammatory activation early during acute
pancreatitis. Treatment with M2 cytokines could revert in vitro the pancreatitis-induced activation
of macrophages but fails to modulate its activation in vivo. This treatment has only a moderate effect
in reducing the systemic inflammation associated to acute pancreatitis. Hydrolytic enzymes
presents in ascitic fluid could be involved in the degradation of cytokines, strongly reducing its utility
to modulate peritoneal macrophages in pancreatitis.
Background
Acute pancreatitis is an inflammatory process of the pan-
creatic gland that in the severe forms involves remote
organ systems. Systemic inflammatory response syn-
drome (SIRS) is one of the major pathobiologic processes
underlying severe acute pancreatitis. This is of major
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importance because half of deaths in the first weeks of the
process are attributed to organ failure, and in particular
the acute respiratory distress syndrome, associated with
SIRS [1]. Despite advances in diagnosis and treatment of
inflammatory pancreatic disease, to date, supportive care
remains the only treatment for patients with pulmonary
complications [2].
Several proinflammatory mediators have been identified
to play a role in the progression of the local pancreatic
damage to the systemic inflammation. This includes
tumor necrosis factor α (TNFα), interleukin (IL)-1β, IL-6,
MCP-1 or Platelet activating factor [3]. Some of these
mediators are released by pancreatic acinar cells and
results in the recruitment of neutrophils and monocytes.
In addition, other inflammatory cell populations contrib-
ute to the systemic generation of inflammatory mediators.
In particular, it has been reported that peritoneal macro-
phages, alveolar macrophages and Kupffer cells become
activated in the early stages of severe acute pancreatitis [4-
6]. Since macrophages orchestrate both the initiation and
the resolution of inflammation, it is suspected that the
degree of macrophage activation could be one of the fac-
tors that finally determine the severity of the process.
However, macrophages could be activated in different
pathways. The initial inflammatory response is mediated
by classically activated macrophages (M1) while the reso-
lution phase is carried out by alternatively activated (M2)
macrophages [7]. M1 macrophages are induced by IFNγ or
LPS and synthesize and release constitutive amounts of
inflammatory mediators such as TNFα, IL-1β, IL-6 and
nitric oxide. The biological activities of M1 macrophages
are characterized by its antimicrobial and cytotoxic prop-
erties, related with their role in host responses to infection
or autoimmune diseases. By contrast, M2 macrophages,
that are induced by IL-4 or IL-13, do not generate these
mediators but promote proliferative and angiogenic proc-
esses [8]. These M2 macrophages play a role in modulat-
ing wound healing, suppressing the inflammatory
response and synthesising extracellular matrix.
The characteristics of acute pancreatitis suggest that activa-
tion of macrophages correspond to the classical M1 phe-
notype. However, there are no data about the phenotypic
status of different macrophage populations during the
progression of acute pancreatitis and the relation between
the differentiation to M1 phenotype and the severity of
the disease.
In this work we have used an experimental model of acute
pancreatitis induced by intraductal administration of
sodium taurocholate to evaluate how the progression of
pancreatitis correlates with the M1 activation of perito-
neal macrophages as well as the effect of IL-4 and IL-13,
administered after the induction of pancreatitis, in pre-
venting the M1 activation and inducing the reparative M2
phenotype. We demonstrated that pancreatitis results in
an M1 activation of peritoneal macrophages that could be
reverted in vitro by treatment with IL-4 and IL.13. How-
ever, in vivo administration of these cytokines after induc-
tion of pancreatitis does not modulate the activation of
peritoneal macrophages. The effect of pancreatitis-associ-
ated ascitic fluid (PAAF) on the cytokines could explain
this lack of effects.
Methods
Animals
Male Wistar rats (250–300 g b.w.) were used in all exper-
iments (Charles River, France). Animals were housed in a
controlled environment and fed with standard laboratory
pelleted formula (A04, Panlab, Barcelona, Spain) and tap
water ad libitum. This study conformed to European Com-
munity for the use of experimental animals and the insti-
tutional committee of animal care and research approved
it.
Animal model of acute pancreatitis
Animals (n = 6 each group) were anesthetized with an i.p.
administration of sodium pentobarbital (50 mg/kg). The
biliopancreatic duct was cannulated through the duode-
num and the hepatic duct was closed by a small bulldog
clamp. Pancreatitis was induced by retrograde perfusion
into the biliopancreatic duct of 5% sodium taurocholate
(Sigma, St Louis, Missouri, USA) in a volume of 0.1 ml/
100 g b.w. using a perfusion pump (Harvard Instruments,
Edenbridge, UK) [9]. The same procedure was applied to
control animals but receiving an intraductal perfusion of
saline solution (NaCl 0.9%) instead of taurocholate.
Three or eighteen hours after induction, peritoneal macro-
phages were obtained. Five ml of blood were obtained
from the cava vein, heparinized and centrifuged to obtain
plasma. Ascitic fluid, and samples of pancreas, white adi-
pose tissue (WAT) and lung were also obtained, immedi-
ately frozen and stored at -80°C until used.
In a second experiment, IL-4 (4 μg/kg) and IL-13 (4 μg/kg)
were i.p. administered to an additional group 1 h after the
induction of pancreatitis. In these animals, macrophages,
plasma and tissue samples were obtained three hours after
the induction of pancreatitis.
Isolation and culture of macrophages
Peritoneal macrophages were harvested by 5 peritoneal
washes with 10 ml of phosphate buffered saline (PBS)
containing 3 units/ml heparin. The obtained cell suspen-
sion was centrifuged (300 × g; 7 min). Cells were sus-
pended in the RPMI1640 culture medium containing
10% fetal calf serum, 2 mM glutamine, penicillin (100 U/
ml) and streptomycin (100 μg/ml). Aliquots of about 3 ×
106 cells were plated in 6 wells plates and cultured at 37°C
under a gas phase of air/CO2 (95:5). After an attachmentBMC Immunology 2009, 10:42 http://www.biomedcentral.com/1471-2172/10/42
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period of 4 h, the non-adherent cells were removed by
shaking. The resulting adherent population consisted of >
92% macrophages as judged by CD68 staining measured
by flow cytometry.
In vitro reversion of phenotypic changes in macrophages
Peritoneal macrophages obtained from control animals as
well as animals 18 hours after pancreatitis induction were
incubated for 24 h with IL-4/IL-13 (10 ng/ml each) in
order to evaluate their capacity to reverse the acquired M1
phenotype. This mixture of cytokines has been reported to
be more effective than IL-4 or IL-13 alone on inducing an
M2 phenotype in macrophages [10]. After the incubation
period RNA was obtained and the expression of TNFα and
Mannose Receptor were evaluated by quantitative RT-
PCR.
Degradation of IL-4 in ascitic fluid and plasma
To evaluate the effect of hydrolytic enzymes presents in
ascitic fluid or plasma during pancreatitis on the stability
of interleukins, the half life of IL-4 on these biological flu-
ids has been determined. Plasma or ascitic fluid obtained
from animals with pancreatitis were pooled and over-
loaded with IL-4 (25 pg/ml). Samples were incubated at
37°C for 2 h, 1 h, 30 min and 15 min after the addition
of IL-4 and the concentration of IL-4 was measured by
ELISA. The experiment has been carried out by triplicate.
RNA isolation and RT-PCR
Total RNA from cells was extracted using the TRizol® rea-
gent (Invitrogen, Carlsbad, CA). The RNA was quantified
by measurement of the absorbance at 260 and 280 nm
using a NanoDrop ND-1000 spectrophotometer (Nano-
Drop Technologies, USA).
cDNA was synthesized using the iScript cDNA synthesis
kit (Bio-Rad Laboratories, Hercules, CA), and reverse tran-
scription was then performed on 1 μg RNA sample by
adding iScript reagents. The reaction was incubated at
25°C for 5 min, 42°C for 30 min, and 85°C for 5 min,
and then stored at -80°C.
Subsequent PCR amplification was performed in a DNA
Engine, Peltier Thermal Cycler (Bio-Rad Laboratories, CA,
USA) using IQTM SYBR Green Super mix and the corre-
spondent rat primers: TNFα forward: 5'-AACTCCCA-
GAAAAGCAAGCA-3' reverse: 5'-
CGAGCAGGAATGAGAAGAGG-3'; Mannose Receptor
forward: 5'-GCAGGTGGTTTATGGGATGT-3' Reverse: 5'-
GGGTTCAGGAGTTGTTGTGG-3'; GAPDH forward: 5'-
CTGTGTCTTTCCGCTGTTTTC-3' and reverse: 5'-TGTGCT-
GTGCTTATGGTCTCA-3'.
Initial denaturation was followed by 40 cycles of DNA
amplification with fluorescence detection at the end of the
elongation step (SYBR Green format). Reactions were per-
formed in duplicate and threshold cycle values were nor-
malized to GAPDH gene expression. The specificity of the
products was determined by melting curve analysis. The
ratio of the relative expression of target genes to GAPDH
was calculated by using the ΔC(t) formula.
Lipase
Plasma lipase was determined by using commercial turbi-
dimetric assay kits from Randox (Antrim, U.K.), according
to the supplier's specifications.
Myeloperoxidase
Neutrophilic infiltration was assessed by measuring mye-
loperoxidase (MPO) activity. MPO was measured photo-
metrically with 3,3',5,5'-tetramethylbenzidine as a
substrate. Tissue samples were homogenized with 0.5%
hexadecyltrimethylammonium bromide in 50 mM phos-
phate buffer at pH 6.0. Homogenates were disrupted for
30 seconds using a Labsonic sonicator (Braun Biotech,
Inc., Allentown, PA) at 20% power and submitted to three
cycles of snap freezing in dry ice and thawing before a
final 30 second sonication. Samples were incubated at
60°C for 2 hours and then spun down at 4000 g for 12
minutes. The supernatants were collected for MPO assay.
Enzyme activity was assessed photometrically at 630 nm.
The assay mixture consisted of 20 μl supernatant, 10 μl
tetramethylbenzidine (final concentration 1.6 mM) dis-
solved in DMSO, and 70 μl H2O2 (final concentration 3.0
mM) diluted in 80 mM phosphate buffer, pH 5.4. The
results are expressed as units (U) MPO activity per g pro-
tein.
Statistical analysis
Data have been expressed as mean ± SEM. Means of differ-
ent groups were compared using a one-way analysis of
variance. Tukey's multiple comparison test was performed
for evaluation of significant differences between groups.
Differences were assumed to be significant when p < 0.05.
Results
Pancreatitis induction
Acute pancreatitis results in a significant increase in lipase
levels in plasma at 3 and 18 hours after induction. The
inflammatory process, evaluated as MPO activity indi-
cates a strong leukocyte infiltration in pancreas, WAT and
lung at both time periods (figure 1).
Macrophage activation
Analysis of peritoneal macrophage activation indicates
that 3 hours after induction it is induced a strong expres-
sion of TNFα. At this time point there was no significant
changes in Mannose Receptor expression, indicating the
activation following the expected M1 phenotype. Interest-
ingly, 18 hours after induction, the expression of TNFαBMC Immunology 2009, 10:42 http://www.biomedcentral.com/1471-2172/10/42
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remains induced but in a less intense level while Mannose
Receptor remained unchanged (figure 2).
In vitro reversibility of the phenotype
Peritoneal M1 activated macrophages are important
sources of pro-inflammatory cytokines that could contrib-
ute to the induction and maintaining of the systemic
inflammatory status. Consequently in order to design
therapies focussed on modulating macrophages activity it
is of interest to evaluate the capacity of these cells to
change their phenotype. With this purpose we treated in
vitro  peritoneal macrophages obtained 18 hours after
inducing pancreatitis, with IL-4 plus IL-13, which are
known to induce a M2 phenotype in macrophages [11].
Results indicate that incubation with these cytokines in
vitro results in the reversion of the M1 phenotype and in
an increased expression of Mannose Receptor, an M2
related gene (figure 3).
In vivo treatment with M2 cytokines
The reversion of M1 phenotype of activated macrophages
during the acute phase of pancreatitis could be an interest-
ing therapeutical approach. With this purpose an addi-
tional group of animals was treated with IL-4 and IL-13
one hour after the induction of the disease. Two hours
later (this is three hours after the induction of pancreati-
Lipase and MPO activity in pancreas, lung and white adipose tissue (WAT) 3 and 8 hours after induction of pancreatitis Figure 1
Lipase and MPO activity in pancreas, lung and white adipose tissue (WAT) 3 and 8 hours after induction of 
pancreatitis. * = p < 0.05 vs. control.BMC Immunology 2009, 10:42 http://www.biomedcentral.com/1471-2172/10/42
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tis), we evaluated the progression of the inflammatory
process as well as the changes in the phenotype acquired
by the peritoneal macrophages.
Administration of M2 cytoquines has no effect on the M1
activation of peritoneal macrophages (figure 4). However,
it results in a decrease in the inflammatory response
observed in the lung and WAT (figure 5). As expected,
cytokine treatment does not modify the pancreatic dam-
age or inflammation and lipase as well as MPO in pan-
creas remained unchanged (figure 5).
When measuring the concentrations achieved of IL-4 in
plasma no measurable levels were found even after the
intraperitoneal administration of interleukins.
Degradation of IL-4 in ascitic fluid
Measures of PAAF overloaded with IL-4 revealed a fast
degradation of the cytokine in this biological fluid. A half
life of 16.4 min was obtained, contrasting with the higher
stability observed in plasma, with a half life of 51.1 min
(Figure 6).
Discussion
Systemic inflammation is a major complication of severe
acute pancreatitis being the associated acute lung injury
and renal failure characteristics of the end stages of the
process. Measurements of cytokines in plasma of patients
or in experimental models revealed increases in inflam-
matory mediators, including TNFα, IL-1, IL-6, MIP2, or
MCP in a situation defined as "cytokine storm" that
results in an uncontrolled inflammatory process in several
organs [12].
In this context, macrophages play a pivotal role due to
their ability to generate pro or anti-inflammatory media-
tors that control the progression of the inflammatory
process. Different reports demonstrate the involvement of
activated peritoneal, alveolar or hepatic macrophages in
the pathogenesis of acute pancreatitis [5,6]. This central
role in the regulation of inflammation made the macro-
phages interesting targets in order to design therapeutical
strategies focussed in the control of the systemic effects of
acute pancreatitis.
In this work we observed that peritoneal macrophages
showed an early and intense M1 activation reflected in the
high expression of TNFα, and the lack of changes in Man-
nose Receptor. This could be observed three hours after
induction and remains in similar phenotypic profile at 18
h. The main difference between these two time periods is
the reduction in the expression of TNFα. This fact agrees
with the kinetics observed in several in vitro experiments
when macrophages are stimulated with pro-inflammatory
mediators. The initial peak of TNFα generation is fol-
lowed by the expression of other cytokines, mainly IL-1β
and IL-8.
This activation was expected since peritoneal macro-
phages are in the peritoneal cavity, in direct and early con-
Changes in the mRNA expression of TNFα and mannose receptor in peritoneal macrophages evaluated by RT-PCR Figure 2
Changes in the mRNA expression of TNFα and mannose receptor in peritoneal macrophages evaluated by 
RT-PCR. Results are expressed as increases with respect to the control group. * = p < 0.05 vs. control.BMC Immunology 2009, 10:42 http://www.biomedcentral.com/1471-2172/10/42
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tact with mediators released by pancreatic tissue. Ascitic
fluid generated in the severe acute pancreatitis contains
pancreatic enzymes and cytokines in a concentration that
exceeds that observed in plasma in on order of magnitude
[13]. The M1 phenotype induced by these mediators can
increase the inflammatory response associated with acute
pancreatitis through the release of other macrophage-
derived inflammatory cytokines. However, several works
reported on the plasticity of activation phenotype
acquired by macrophages and their capability to be repro-
grammed by the effect of M1 or M2 cytokines [11,14].
Consequently, it could be of interest to known the capac-
ity of these pancreatitis-activated peritoneal macrophages
to be reverted to an antiinflammatory and reparative M2
phenotype. We have evaluated this possibility in vitro by
treating pancreatitis-activated peritoneal macrophages
with a mixture of IL-4 and IL-13. These cytokines are
known to induce the alternative M2 activation of macro-
phages, promoting the repair phenotype and counteract-
ing the effects of pro-inflammatory cytokines [7].
Results indicate that activated peritoneal macrophages
obtained during pancreatitis could be re-directed to M2
phenotype by the effect of IL-4 and IL-13 treatment (figure
3). This was evidenced by the reduction in TNFα expres-
sion that parallels with the induction of Mannose Recep-
tor.
Reversibility of macrophage phenotype was observed on  incubating peritoneal macrophages obtained 18 hours after  pancreatitis induction and incubated with a mixture of IL-4  plus IL-13 for 24 hours Figure 3
Reversibility of macrophage phenotype was observed 
on incubating peritoneal macrophages obtained 18 
hours after pancreatitis induction and incubated with 
a mixture of IL-4 plus IL-13 for 24 hours. This treat-
ment resulted in the inhibition of TNFα expression as well as 
the induction of Mannose receptor in both control and AP 
macrophages. Results are expressed as increases with 
respect to the control group. * = p < 0.05 vs. control; + = p 
< 0.05 vs AP.
In vivo administration of IL-4 plus IL-13 does not accomplish  to reduce the macrophages activation in the early stages of  pancreatitis Figure 4
In vivo administration of IL-4 plus IL-13 does not 
accomplish to reduce the macrophages activation in 
the early stages of pancreatitis. No changes were 
observed in TNFα or Mannose receptor expression in peri-
toneal macrophages. Results are expressed as increases with 
respect to the control group. * = p < 0.05 vs. control.BMC Immunology 2009, 10:42 http://www.biomedcentral.com/1471-2172/10/42
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In a subsequent experiment we tried to modulate in vivo
the activation of peritoneal macrophages. For this pur-
pose, interleukins 4 and 13 were administered i.p. one
hour after the induction of pancreatitis and two hours
later we evaluated the progression of the inflammatory
process as well as the activation of macrophages. This was
a short time period to achieve a complete M2 phenotype,
but the fast progression of the disease do not allows pro-
longed treatments. The objective was only to achieve a
reduction in the intensity of the M1 activation that could
result in a decrease in the systemic inflammation.
As expected, interleukins treatment 1 h after induction has
no effect on the pancreatic tissue damage which, in this
model of pancreatitis, is directly induced by the effect of
taurocholate on acinar cells. This was evident by the lack
of changes in the increased plasma lipase activity. Pan-
creas inflammation also was unmodified according the
MPO results. By contrast, a moderate but significant
reduction in lung and WAT inflammation was observed
(figure 5). However, these changes appear to be unrelated
with the peritoneal macrophage activation because the
M1 phenotype induced by pancreatitis remains similar to
that observed in the non-treated group (figure 4).
It has been observed in several experimental models that
IL-4 could modulate the regulation of complement activa-
tion [14] or the generation of IL-10 in chronic pancreatitis
[15]. Some of these effects could explain the reduction in
the inflammation observed in our experimental condi-
Effect of IL-4 and IL-13 administration on the progression of the early stages of inflammation Figure 5
Effect of IL-4 and IL-13 administration on the progression of the early stages of inflammation. No changes were 
observed in lipase activity in plasma or in MPO levels in pancreas. By contrast, a significant inhibition of MPO in lung and white 
adipose tissue (WAT) indicates a reduction of the systemic inflammation. * = p < 0.05 vs. control; + = p < 0.05 vs AP.BMC Immunology 2009, 10:42 http://www.biomedcentral.com/1471-2172/10/42
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tions. However, it is clear that interleukin administration
was not enough to therapeutically modulate the M1 phe-
notype observed in peritoneal macrophages. This lack of
changes after M2 cytokines administration could be
related with the strong proinflammatory environment
generated in the peritoneal cavity, but also by the hydro-
lytic activity of ascitic fluid.
In this sense, when measuring the stability of IL-4 in
ascitic fluid we observed a fast degradation of this
cytokine. These changes were not observed in plasma and
could be related with the hydrolytic enzymes released by
pancreatic tissue to the ascitic fluid. This fact also explains
the lack of measurable increases in IL-4 levels in plasma of
treated animals. It must be pointed out that the intraperi-
toneal administration of cytokines was selected since our
objective was to act on peritoneal macrophages. Conse-
quently, the administration of cytokines to modulate the
activation of macrophages during the progression of acute
pancreatitis appears to be useful for act on several cell
populations but not for the peritoneal macrophages.
Conclusion
Our results indicate that peritoneal macrophages adopt a
pro-inflammatory activation early during acute pancreati-
tis and that they could be reprogrammed in vitro to a
reparative M2 phenotype by IL-4 and IL-13. However, in
vivo this treatment has only a moderate effect in reducing
the systemic inflammation and fails to prevent the perito-
neal macrophage activation. This lack of effect seems to be
related with the degradation of interleukins by the action
of ascitic fluid present in the peritoneal cavity. Conse-
quently, different therapeutic approaches will be needed
to modulate the activation of this cell population for the
treatment of severe acute pancreatitis.
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